The field of the invention is stems cells and reagents for same, and especially as they relate to adult-derived transitional blastomere-like stem cells and regenerative pluripotent stem cells.
It is currently thought that mammalian cells progress from embryonic cell stages to fully developed cells through a sequence of totipotent blastomeric cells that transition into pluripotent epiblastic cells, which transition into germ layer lineage cells, which transition into multipotent progenitor cells that transition into tripotent, then bipotent, then unipotent progenitor cells and finally develop into the differentiated parenchymal and stromal cell types (
Remarkably, while the vast majority of developing cells transition through that sequence of developmental and differentiation events, a few cells become reserve precursor cells (
Embryonic stem cells (ESC) are relatively large uncommitted cells isolated from embryonic tissues. For example, ESCs have been isolated as disrupted blastomeres from the morula (
In still further known methods, pluripotent stem cells have been isolated from non-embryonic sources, including from umbilical cord matrix as described in U.S. Pat. App. No. 2003/0161818 and postnatal gonadal tissue as taught in WO 2002/031123. However, while such cells do not require destruction of an embryo and are therefore potentially of interest for human stem cells. However, the cells would be allogeneic in a stem cell transplant and the isolated stem cells have not been demonstrated to be totipotent.
Upon differentiation in vitro all or almost all of these cells express a wide variety of cell types, including gametes, as well as cells derived from the ectodermal, mesoderm, and endodermal germ layer lineages. Unfortunately, when currently known uncommitted embryonic stem cells are implanted into animals, they typically spontaneously differentiate in situ, forming teratomas. These tumors contain various types of cells and tissue derived from all three primary germ layer lineages [Thomson et al., 1988]. Therefore, while embryonic stem cells appear to have therapeutic potential in transplantation therapies their tendency to differentiate spontaneously in an uncontrolled manner places limitations on their usefulness.
Induced pluripotent stem (iPS) cells are generated from adult differentiated somatic cells by the insertion of embryonic genes [Yamanaka. 2009; Jalving and Shepers, 2009; Yamanaka and K. Takahashi, 2012]. The iPS cells were created to bypass the ethical and moral issues of dealing with embryonic and/or fetal tissues, since they were initially produced from adult differentiated somatic cells. Induced pluripotent stem cells express embryonic characteristics. They have capabilities for differentiation similar to embryonic stem cells, and are readily available for study. With respect to regenerative medicine, iPS cells are similar to embryonic stem cells. iPS cells spontaneously differentiate in culture in the absence of differentiation inhibitors. And like embryonic stem cells [Yamanaka. 2009], iPS cells form teratomas when placed in vivo in a naive undifferentiated state [Yamanaka and K. Takahashi, 2012]. Unfortunately, the production of teratomas reduces the utility of iPS cells as a source of stem cells for medical therapies. To avoid teratoma formation, iPS and embryonic stem cells must both be induced outside the body, i.e., ex vivo, to differentiate into the desired cell type before transplantation. Once induced, these cells lose their innate plasticity upon differentiation. This is the central dilemma for the use of embryonic stem cells or iPS cells in regenerative medicine. If one avoids differentiation ex vivo, teratomas result. If one differentiates these cells to avoid teratoma formation, then the resulting cells lose plasticity and gain a limited life-span.
Adult blastomeric-like stem cells can be isolated from autologous or allogeneic individuals. They range in size from 2.0 microns to less than 0.2 microns in size (FIGS. 4,5), as determined by flow cytometry of living cells (
Adult blastomeric-like stem cells display a normal karyotype (
Adult totipotent blastomeric-like stem cells remain quiescent in vitro in a serum-free environment lacking proliferation agents, lineage-induction agents, progression agents, and/or inhibitory factors, such as recombinant human leukemia inhibitory factor (LIF), recombinant murine leukemia inhibitory factor (ESGRO), or recombinant human anti-differentiation factor (ADF) (similar to
Adult pluripotent epiblast-like stem cells (ELSCs) are 6-8 microns in size as assessed by flow cytometry of living cells (Table 1, FIGS. 5,13) [Young et al., 1999]. ELSCs have the potential to form all the downstream somatic cells of the body (FIGS. 14,15) [Young et al., 2004a,b]. ELSCs will not form totipotent blastomeric-like stem cells, gametes (ovum and sperm) or their precursor cells (oogonia or spermatogonia) [Young and Black, 2005a]. Adult pluripotent epiblast-like stem cells are telomerase positive (
Studies have located the adult regenerative stem cells in the blood and in the supportive connective tissues of most organs. For example, both SSEA positive cells (ELSCs) and CEA-CAM-1 positive cells (BLSCs) were found in adult rat (RM1021) heart (
Propagation of human and mammalian stem cells for transplantation therapies typically occurs ex vivo. The growth medium for most stem cells grown in culture is routinely supplemented with animal and/or human serum to optimize and enhance cell viability (Young et al., 1992, 1993, 1998b, 2001b; Young, 1999b; Young and Black, 2012; Pate et al, 1993; Rogers et al., 1995; Lucas et al., 1995, Warejcka et al., 1996; Dixson et al., 1996; Centeno et al., 2009). The constituents of serum include water, amino acids, glucose, albumins, immunoglobulins, and one or more bioactive agents. Potential bioactive agents present in serum include agents that induce proliferation, agents that accelerate phenotypic expression, agents that induce differentiation, agents that inhibit proliferation, agents that inhibit phenotypic expression, and agents that inhibit differentiation (Young et al., 1998, 2004b). Unfortunately, the identity(ies), concentration(s), and potential combinations of specific bioactive agents contained in different lots of serum is/are unknown (Young et al., 1998, 2004b). One or more of these unknown agents in serum have shown a negative impact on the isolation, cultivation, cryopreservation, and purification of lineage-uncommitted blastomere-like stem cells. Similarly, where feeder layers for stem cells were employed, contamination of stem cell cultures with feeder layer specific components, and especially viruses frequently occurs (Young et al., 2004b).
Alternatively, serum-free media are known for general cell culture, and selected pluripotent stem cells have been propagated in such medium containing a plurality of growth factors as described in US20050164380, US20030073234, U.S. Pat. No. 6,617,159, U.S. Pat. No. 6,117,675, or EP1298202.
Isolation of various types of progenitor cells, mesenchymal stem cells, epiblast-like stem cells, or blastomeric-like stem cells usually occurs by centrifugation, enzymatic digestion, cryopreservation, cell sorting, and/or cloning (
Multiple techniques have been used to transplant stem cells into animal models for tissue repair. Methods for cell suspensions include the use of small diameter hollow bore instruments (needles, cannulae) for intravenous infusion, direct needle injection, stereotactic injection, intrathecal injection, etc. and spraying directly on the tissue surface. Alternative methods have used placement within a bio-protective material, bio-protective/bio-degradable material or other such material that protects the cells from the immune system of the host while allowing it to function in its normal capacity [Young et al., 1989a, 1990c; Shoptaw et al., 1991; Bowerman et al., 1991].
Thus, while numerous compositions and methods for stem cells are known in the art, all or almost all of them suffer from one or more disadvantages. Therefore, there is still a need for improved stem cells, compositions, and reagents for their production, maintenance, and differentiation, and especially for ease of use for transplantation therapies.
Anyone skilled in the art will understand that this technology has the potential to treat ALL somatic body tissues involved in congenital malformations, trauma, disorders, and diseases of any of the systems in humans and other mammals. Those conditions include neurological, pulmonary, gastrointestinal, urinary, orthopedic, autoimmune, third degree burns, and any other anomaly dealing with cells within the body, EXCEPT the germ cells (sperm and ova) in the reproductive organs. Various objects, features, aspects and advantages of the present invention will become more apparent from the following detailed description of preferred embodiments of the invention.
The following descriptions and protocols are provided to give exemplary guidance to a person to make and use various aspects of the inventive subject matter presented herein. However, it should be appreciated that numerous modifications can be made without departing from the spirit of the present disclosure. Further contemplations, considerations, and experimental details are provided in WO 01/21767, U.S. Pat. App. Nos. 2003/0161817, and 2004/0033214, all of which are incorporated by reference herein.
Bleach Solution: 0.5% Sodium hypochlorite (undiluted Clorox).
Disinfectant: The disinfectant of choice is Amphyl solution: 0.5% (v/v) in deionized water. In a 20 L carboy add 100 ml of Amphyl and then add 20 L of deionized water. However, 70% ethanol or other disinfectants not harmful to the cells may be utilized.
70% (v/v) Ethanol: Dilute 95% ethanol to 70% (v/v) with double deionized water. In a 500 ml glass media bottle, mix 368.4 ml of 95% ethanol with 131.6 ml of double deionized water. Store solution at ambient temperature.
70% (v/v) Isopropyl alcohol. Purchased from local Wal-Mart. Use at designated concentration of 70%.
Sterile 5M sodium hydroxide: Weigh out 20 g of sodium hydroxide granules (catalog #S318, Fisher Scientific, Pittsburgh, Pa.) and add to a glass media bottle. Very slowly add 100 ml of double deionized water to the sodium hydroxide granules. Once the sodium hydroxide is dissolved, filter sterilizes the solution through a 0.1 μm bottle top vacuum filter. Store solution at ambient temperature.
Sterile 5M hydrochloric acid: Measure 58.3 ml of double deionized distilled water and place in a 100-ml glass media bottle. Measure 41.7 ml of 12 M HCl (catalog #5619-02, VWR, JT5619-2, Bristol, Conn.) and very slowly add to water. Place cap on bottle and swirl gently to mix contents. Filter sterilizes the solution through a 0.1 μm bottle top vacuum filter. Store contents at ambient temperature.
0.4% Trypan Blue solution: Weigh out 0.2 g of Trypan blue (catalog #11618, Eastman Kodak Company, Rochester, N.Y.) and place in a sterile 100 ml glass media bottle. Under sterile conditions using a 25 ml pipette, add 50 ml of sterile Rinse buffer (catalog #MBC-ASB-REB-200-A001, Moraga Biotechnology Corp., Los Angeles, Calif.) containing 1% (or 1 ml of the 100×) antibiotic-antimycotic solution (catalog #15240-104, GIBCO), at pH 7.4. Swirl bottle gently to dissolve the Trypan blue powder. Filter sterilize the Trypan blue solution through a 0.2 μm bottle-top vacuum filter. Store this solution at ambient temperature.
Sterile Rinse Buffer with Ca+2/Mg+2, pH 7.4: Under sterile conditions, take a fresh 500 ml bottle of sterile Rinse Buffer with Ca+2/Mg+2 (catalog #MBC-ASB-REB-200-A001, Moraga Biotechnology Corp., Los Angeles, Calif.), discard 5 ml to bleach, and then add 5 ml of the 100× antibiotic-antimycotic solution (catalog #15240-104, GIBCO), for a final concentration of 1×. Invert the bottle a few times to mix the solution, and bring the pH to 7.4 using sterile 5M sodium hydroxide. Store solution at 4° C.
Sterile Release Buffer without Ca+2/Mg+2, pH 7.4: Under sterile conditions, take a fresh 500 ml bottle of sterile Release Buffer without Ca+2/Mg+2 (catalog #MBC-ASB-REB-200-A002, Moraga Biotechnology Corp.), discard 5 ml to bleach, and then add 5 ml of the 100× antibiotic-antimycotic solution (catalog #15240-104, GIBCO), for a final concentration of 1×. Invert the bottle a few times to mix the solution, and bring the pH to 7.4 using sterile 5M sodium hydroxide. Store solution at 4° C.
Sterile SFD-BLSC Rinse Buffer, Ca+2/Mg+2, pH 7.4: Under sterile conditions, take a fresh 500 ml bottle of sterile serum-free-defined (SFD)-BLSC Rinse Buffer with Ca+2/Mg+2 (catalog #MBC-ASB-REB-100-A001, Moraga Biotechnology Corp.), discard 5 ml to bleach, and then add 5 ml of the 100× antibiotic-antimycotic solution (catalog #15240-104, GIBCO), for a final concentration of lx. Invert the bottle a few times to mix the solution, and bring the pH to 7.4 using sterile 5M sodium hydroxide. Store solution at 4° C.
Sterile SFD-BLSC Release Buffer without Ca+2/Mg+2, pH 7.4: Under sterile conditions, take a fresh 500 ml bottle of sterile serum-free defined (SFD) BLSC Release Buffer without Ca+2/Mg+2 (catalog #MBC-ASB-REB-100-A002, Moraga Biotechnology Corp.) and discard 5.0 ml to bleach. Add 5 ml of the 100× antibiotic-antimycotic solution (catalog #15240-104, GIBCO) to the glass bottle (final concentration of 1×). Swirl to mix contents. pH to 7.4 with 5 M sodium hydroxide and/or 5 M hydrochloric acid. Store this solution at 4° C.
Dexamethasone solution, pH 7.4: This is typically made up in absolute ethanol (EtOH) because it is not soluble in water or media. Weigh out 0.039 gm of Dexamethasone (Dex, catalog #D-1756, Sigma) and add to 10 ml of absolute EtOH. This will make a 1×10−2 M stock solution. Store this solution at −20° C. This is the most concentrated solution of Dex that can be made with complete solubility. Add 1 ml of the stock Dex solution made above to 9-ml Opti-MEM I medium with Glutamax. Aliquot 9 ml of this solution as 500 μl quantities in 2 ml cryovials and store at −20° C. Label these tubes as 1×10−6M Dex. Take the remaining 1 ml of 10−6M Dex and add to 9 ml of Opti-MEM I medium with Glutamax. Aliquot 9 mls and reserve 1 ml as before. Label these tubes as 1×10−7M Dex. Take the remaining 1 ml of 10−7M Dex and add to 9 ml of Opti-MEM I medium with Glutamax. Aliquot 9 mls and reserve 1 ml as before. Label these tubes as 1×10−8M Dex. Take the remaining 1 ml of 10−8M Dex and add to 9 ml of Opti-MEM I medium with Glutamax. Aliquot 9 mls and reserve 1 ml as before. Label these tubes as 1×10−9M Dex. Take the remaining 1 ml of 10−9M Dex and add to 9 ml of Opti-MEM I medium with Glutamax. Aliquot all 10 mls. Label these tubes as 1×10−10M Dex. These aliquots will bring 500 mls of media to the concentration of Dex labeled on the tube. Store the cryovials at −20° C.
Insulin solution, pH 7.4: Weight out 100 mg of Insulin (catalog #1-5500, Sigma) and add to a 15 ml conical. Under sterile conditions, add 5.0 ml of Opti-MEM I media with Glutamax to the conical. Invert the conical to dissolve the insulin. Filter sterilize twice using a 0.2 μm syringe filter, into a 15 ml conical first and then a 50 ml conical the second time. Measure volume present using a 5 ml pipette. Add enough Opti-MEM I media with Glutamax to bring the volume up to 15 mls. The final concentration will be approximately 1 mg/500 μl. Aliquot this solution into 1-ml cryovials, 500 μl each. Store the cryovials at −20° C. One cryovial will bring 500 mls of media up to the final concentration of 2 micrograms/ml.
Sterile Serum-Free Defined BLSC Media Supplements, pH 7.4: Under sterile conditions remove 7.975 ml from 500-ml bottle of sterile tissue culture medium of choice (e.g., EMEM, RPMI, Opti-MEM, or etc.) and discard to bleach. Add 7.975-ml aliquot of SFD-BLSC Media Supplements (catalog #MBC-ASB-MED-100-A001, Moraga Biotechnology Corp.) and swirl the bottle gently to mix contents. Remove 5.0 ml of solution and discard to bleach. Add 5 ml Antibiotic-Antimycotic solution. Swirl the bottle gently to mix contents and pH to 7.4. Store at 4° C.
Serum-Free Defined BLSC Basal Medium, pH 7.4: Under sterile conditions remove 5.0 mls from 500 ml bottle of Serum-Free Defined BLSC Basal Medium (catalog #MBC-ASB-MED-100-A002, Moraga Biotechnology Corp.) and discard to bleach. Add 5 ml Antibiotic-Antimycotic solution. Swirl the bottle gently to mix contents and pH to 7.4. Store at 4° C.
Propagation Supplement, pH 7.4: Under sterile conditions remove 6.0 mls from 500 ml bottle of medium supplemented with Serum-Free Defined BLSC Media Supplements (catalog #MBC-ASB-MED-100-A001, Moraga Biotechnology Corp.) and discard to bleach. Add 1.0 ml of Propagation Supplement (catalog #MBC-ASB-MED-100-A003, Moraga Biotechnology Corp.) and 5 ml of Antibiotic-Antimycotic solution. Swirl the bottle gently to mix contents and pH to 7.4. Store at 4° C.
Serum-Free Defined BLSC Propagation medium, pH 7.4: Under sterile conditions remove 5.0 mls from 500 ml bottle of Serum-Free Defined BLSC Propagation medium (catalog #MBC-ASB-MED-100-A006, Moraga Biotechnology Corp.) and discard to bleach. Add 5 ml Antibiotic-Antimycotic solution. Swirl the bottle gently to mix contents and pH to 7.4. Store at 4° C.
Serum-Free Defined BLSC Transport medium, pH 7.4: Under sterile conditions remove 15.0 mls from 500 ml bottle of Serum-Free Defined BLSC Transport medium (catalog #MBC-ASB-MED-100-A004, Moraga Biotechnology Corp.) and discard to bleach. Add 15 ml Antibiotic-Antimycotic solution. Swirl the bottle gently to mix contents and pH to 7.4. Store at 4° C.
Serum-Free Defined BLSC Cryopreservation medium, pH 7.4: Under sterile conditions, take a fresh 100 ml bottle of Serum-Free Defined BLSC Cryopreservation Medium, pH 7.4 (catalog #MBC-ASB-MED-100-A005, Moraga Biotechnology Corp.). Remove 1.0 ml of medium and discard to bleach. Add 1 ml Antibiotic-Antimycotic solution. Swirl the bottle gently to mix contents and pH to 7.4. Store at 4° C.
General Induction medium, pH 7.4: Serum-Free Defined BLSC Propagation Medium, pH 7.4, containing 10−8 M dexamethasone, 2 μg/ml insulin, 5% SS9, and 10% SS12. Under sterile conditions, take a fresh 500 ml bottle of SFD-BLSC Propagation medium (catalog #MBC-ASB-MED-100-A006, Moraga Biotechnology Corp.) remove 83 ml of medium and place into a sterile 100-ml bottle. Add 500 μl aliquot of insulin, 500 μl aliquot of dexamethasone, 5-ml of SS9 (catalog #H7889, Sigma), and 10-ml of SS12 (catalog #FB-01, Omega Scientific, Tarzana, Calif.). Swirl the bottle gently to mix solutions, pH to 7.4 and store at 4° C.
Ectodermal Induction medium, pH 7.4: Serum-Free Defined BLSC Propagation medium, containing 10−8 M dexamethasone, 2 μg/ml insulin, and 15% SS12, pH 7.4. Under sterile conditions, take a fresh 500 ml bottle of Serum-Free Defined BLSC Propagation medium, pH 7.4, and remove 83 ml of medium and place into a sterile 100-ml bottle. Add 500 μl aliquot of insulin, 500 μl aliquot of dexamethasone, 15-ml of SS12 (catalog #FB-01, Omega Scientific, Tarzana, Calif.). Swirl the bottle gently to mix solutions and store at 4° C.
Mesodermal Induction medium, pH 7.4: Serum-Free Defined BLSC Propagation medium, containing 10−8 M dexamethasone, 2 μg/ml insulin, and 10% SS9, pH 7.4. Under sterile conditions, take a fresh 500 ml bottle of Serum-Free Defined BLSC Propagation medium, pH 7.4, and remove 83 ml of medium and place into a sterile 100-ml bottle. Add 500 μl aliquot of insulin, 500 μl aliquot of dexamethasone, 10-ml of SS9 (catalog #H7889, Sigma). Swirl the bottle gently to mix solutions and store at 4° C.
Endodermal Induction medium, pH 7.2: Serum-Free Defined BLSC Propagation medium, containing 10−8 M dexamethasone, 2 μg/ml insulin, and 15% SS12, pH 7.4. Under sterile conditions, take a fresh 500 ml bottle of Serum-Free Defined BLSC Propagation medium, pH 7.4, and remove 83 ml of medium and place into a sterile 100-ml bottle. Add 500 μl aliquot of insulin, 500 μl aliquot of dexamethasone, 10-ml of SS12 (catalog #FB-01, Omega Scientific, Tarzana, Calif.). pH to 7.2 with 6 M HC1. Swirl the bottle gently to mix solutions and store at 4° C.
SFD-Tissue Release Solution, pH 7.4: SFD-Tissue Release Solution (catalog #MBC-ASB-RED-100-A003, Moraga Biotechnology Corp.), store the tubes at −20° C. until needed. Just before use, thaw, remove 1% solution and discard to bleach. Add 1% antibiotic-antimycotic solution and pH to 7.4.
SFD-Cell Release/Activation solution, pH 7.4: Under sterile conditions, take a fresh 500 ml bottle of SFD-Cell Release/Activation Solution (catalog #MBC-ASB-RED-100-A004, Moraga Biotechnology Corp.), remove 5.0 ml of solution and discard to bleach. Add 5 ml Antibiotic-Antimycotic solution. Swirl the bottle gently to mix contents and pH to 7.4. Store at 4° C.
SFD-Cell Release/Activation Inhibitor Solution, pH 7.4: Under sterile conditions, take a fresh 500 ml bottle of SFD-Cell Release/Activation Solution Inhibitor (catalog #MBC-ASB-RED-100-A005, Moraga Biotechnology Corp.), remove 5.0 ml of solution and discard to bleach. Add 5 ml Antibiotic-Antimycotic solution. Swirl the bottle gently to mix contents and pH to 7.4. Store at 4° C.
SFD-BLSC-MACS buffer, pH 7.2: Under sterile conditions, take a fresh 500 ml bottle of SFD-BLSC-MACS buffer (catalog #MBC-ASB-RED-100-A006, Moraga Biotechnology Corp.), remove 5.0 ml of solution and discard to bleach. Add 5 ml Antibiotic-Antimycotic solution. Swirl the bottle gently to mix contents and pH to 7.2. Store at 4° C.
Adult Stem Cell Coated culture vessels: 75 cm2 flasks (catalog #MBC-ASB-MSD-900-A006, Moraga Biotechnology Corp.), 25 cm2 flasks (catalog #MBC-ASB-MSD-900-A007, Moraga Biotechnology Corp.), 6-well plates (catalog #MBC-ASB-MSD-900-A008, Moraga Biotechnology Corp.), 24-well plates (catalog #MBC-ASB-MSD-900-A009, Moraga Biotechnology Corp.), 48-well plates (catalog #MBC-ASB-MSD-900-A010, Moraga Biotechnology Corp.), and 96-well plates (catalog #MBC-ASB-MSD-900-A011, Moraga Biotechnology Corp.).
The Parkinson model examined was a 6-hydroxydopamine-induced substantia niagral-lesioned in the midbrain (
We examined two myocardial infarction models in adult male rats. One myocardial infarction model was created by freezing the tip of the left ventricle with liquid nitrogen. The other myocardial infarction model was created by a transient ligation of the left anterior descending coronary artery (LAD).
In the first model system, regenerative pluripotent stem cells (Scl-40β) were injected into the apex of the left ventricle, the animals allowed to recover from one to six weeks and then euthanized, the tissue removed, cryosectioned at 50 microns, stained with Rhodamine, and viewed with a con-focal microscope. After 4 weeks, β-galactosidase containing cells were located in the vasculature, in the healing myocardium, and in the surrounding perimysial connective tissues (
In the second model system, beta-galactosidase histochemistry (blue) of LacZ-genomically-labeled Scl-40β-ELSCs in vitro was shown. Note, there were blue-green stained nuclei, this was indicative that greater than 90% of cells retained genomic material within their respective nuclei after many cell doublings (
An artificial pancreatic organoid was produced using a combinatorial approach. This approach consisted of using decellularized porcine pancreatic matrices (
The present invention is directed to compositions and method related to adult-derived regenerative pluripotent transitional-blastomere-like stem cells that express telomerase and carry surface markers CD10+, SSEA+ and a halo of CD66e+, CEA-CAM-1+, and Trypan blue staining (FIGS. 58,59).
In one aspect of the inventive subject matter, an isolated stem cell is preferably a human post-natal, pluripotent stem cell having surface markers CD10+, SSEA+ and a halo of staining of CD66e+, CEA-CAM-1+, and Trypan blue (
Such cells advantageously differentiate into an epiblast-like stem cell upon stimulation with a differentiating medium, and are known to undergo at least 100 population doublings while maintaining undifferentiated pluripotent characteristics in serum-free medium in the absence of differentiation inhibitors. Thus, these stem cells, according to the inventive subject matter, will typically not spontaneously differentiate in defined serum-free medium in the absence of differentiation inhibitors. Rather, they will remain quiescent and will not form a cancerous tissue when implanted into an animal or human (Table 1).
Such human cells may further be characterized by expression of telomerase, Oct-3/4, Sonic hedgehog, CD66e/CD10 joined cell surface markers (
Previous studies have shown that adult regenerative pluripotent stem cells, i.e., totipotent blastomeric-like stem cells, epiblast-like stem cells, and germ layer lineage stem cells, reside within niches within the connective tissue matrices of the adult differentiated tissues (
As mentioned above, transitional pluripotent blastomere-like stem cells, i.e., those stem cells that occur between the previously defined stem cell types, also are located in the tissues and progress throughout the differentiation pathway. In this case, the stem cell traverses between blastomeric-like stem cells and epiblast-like stem cells. Although the regenerative pluripotent “transitional blastomeric-like stem cells” (Tr-BLSCs) share similar cell surface markers as both blastomere-like stem cells (BLSCs) and epiblast-like stem cells (ELSCs), their size differences and staining peculiarities make them recognizable as a separate regenerative stem cell type (
In still further contemplated aspects, the inventor contemplates a method of multiplying the adult-derived regenerative pluripotent blastomere-like stem cells in situ (in vivo). This was first attempted using Stem Enhance (
We have since discovered a “compound” that, when taken properly, slowly increases the number of daughter stem cells in the blood without depleting the body of its resident supply of mother stem cells (
In still further contemplated aspects, the inventor contemplates a method of harvesting the adult-derived regenerative pluripotent transitional blastomere-like stem cells from their in situ (in vivo) location in the blood. Once the individual takes the appropriate number of compound capsules to increase the number of adult-derived regenerative pluripotent transitional blastomere-like stem cells within the blood, 1.0-ml to 4000.0-ml of blood is removed by sterile venipuncture. The blood is placed into sterile tubes or an IV bag containing EDTA and then placed into a 4 degree centigrade/38 degree Fahrenheit refrigerator for 20 minutes to 96 hours, dependent on the species. Multiple techniques can then be utilized to separate the stem cells, i.e., BLSCs, Tr-BLSCs, ELSCs, and GLSCs from the hematopoietic elements (
Due to the inherent nature of the zeta-potential on the surface of the hematopoietic red blood cells, hematopoietic white blood cells and the adult-derived regenerative pluripotent stem cells, the hematopoietic cells and stem cells self-separate from each other by quantitative polyanionic zeta potential repulsion. The hematopoietic cells precipitate to the bottom of the tube, as the red cell layer with the white cell buffy coat layer on top. The adult-derived regenerative pluripotent stem cells are maintained in the serum layer by the quantitative polyanionic zeta potential repulsion. Depending on the particular species, i.e., mouse, rat, rabbit, cat, dog, sheep, goat, pig, cow, horse, or human, the minimal time for separation of the stem cells can be as few as 20 minutes or as long as 96 hours. The serum layers, containing the adult-derived regenerative pluripotent regenerative pluripotent stem cells, i.e., blastomeric-like stem cells, transitional blastomere-like stem cells, and epiblast-like stem cells, are removed in toto, washed with an equal volume of sterile saline, and centrifuged at high speed for 5 minutes to 60 minutes. The supernatant is removed to sterile saline bags for intravenous (IV) infusion into the individual. The pelleted stem cells are resuspended, pooled, and a small 200 microliter sample is removed for counting. The counted adult-derived regenerative pluripotent stem cells are then used at appropriate quantities to augment tissue repair, where needed. The remaining layers of serum, containing the germ layer lineage stem cells (next to the buffy coat) are removed, pooled, and placed into the sterile saline bags for infusion into the individual. Adult-derived regenerative pluripotent transitional blastomere-like stem cells may be stored up to 30 days from 1-30 degrees centigrade with minimal loss of viability.
In still further contemplated aspects, the inventor contemplates a method of using the adult-derived regenerative pluripotent blastomere-like stem cells for transplantation therapies. Such therapies might include, but are not exclusive to, neurological diseases (i.e., Parkinson's disease, Alzheimer's disease, Dementia, Stroke, Neuropathies, Neuroparesthesias, Sciatica, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Spinal Cord Injury, etc.), cardiovascular diseases (myocardial infarction, cardiac hypertrophy, cardiac ischemia, vascular ischemia, etc.), pulmonary diseases (COPD, IPF, bronchitis, emphysema, asthma, cystic fibrosis, etc.), gastrointestinal diseases (i.e., Celiac disease, Crohn's disease, etc.), urinary diseases (i.e., polycystic kidney disease, urinary bladder obstructions, valvular weakness of the urinary sphincter, etc.); autoimmune diseases (i.e., Hashimoto's thyroiditis, type-I diabetes, scleroderma, lupus, systemic lupus erthythematosus, rheumatoid arthritis, etc.); orthopedic disorders (i.e., bone fractures, bone loss, osteo-arthritis, articular joint destruction, Lyme's disease, rotator cuff tears, articular joint sprain, skeletal muscle tears, ligament and tendon evulsions or tears, cartilage (i.e., elastic, hyaline, growth plate, articular, and fibrocartilage) replacement or repair; burn injuries (preferably third degree burns, but also second and first degree burns); transection of the skin and underlying soft tissues due to trauma or elective surgeries; etc. Typically, implantation of the adult regenerative transitional blastomeric-like stem cell will be into damaged tissues, after scar tissue has been removed, in an elective plastic surgery-type setting, and/or when the tissue is undergoing repair.
The overall objective is to mobilize autologous adult regenerative pluripotent stem cells into the peripheral blood stream in situ, at sufficient quantities to provide a source of autologous adult stem cells for cell, tissue, and organ-associated Parkinson's disease repair. We will use a Parkinson's disease (PD) population. We will assess the core aspects of PD by targeting specific outcomes related to function, cognition, affect and caregiver burden. We will then remove 500-ml of blood after 3 months on ingestion of the “compound” to isolate regenerative pluripotent stem cells. We will do this on three occasions for a year (3 capsules per day, 6 capsules per day, and 8 capsules per day). These autologous stem cells will be isolated from the blood, one-half of the isolated pluripotent stem cells will be infused into the patient's central nervous system via an intra-nasal route, and the remaining half of the isolated pluripotent stem cells will be given back to the peripheral vasculature of the patient via a 500-ml normal saline IV-drip. We will then assess the overall improvement of the cognitive aspects of PD by targeting specific outcomes related to function, cognition, affect and caregiver burden at one month, 3 months, and six months post infusion.
The compound is composed of the following constituents in 0.500 g capsules and containing 500-2500 kCal, i.e., protein 50-100%, fat 0-50%, minerals 1-20%, lipids 1-10%, pigments 1-10%, moisture 1-10%, chlorophyll 50-100%, alpha-linolenic acid (Omega-3) 10-50 mg, gamma-linolenic acid 1-30 mg, provitamin-A beta carotene 400-5000 IU, thiamine (B1) 1-100 mcg, riboflavin (B2) 1-100 mcg, niacin (B3) 1-100 mcg, pantothenic acid (B5) 1-100 mcg, pyridoxine (B6) 1-100 mcg, inositol 1-100 mcg, vitamin D 1-100 mcg, vitamin E 1-100 IU, ascorbic acid (vitamin C) 1-100 mcg, biotin 1-1000 mcg, folic acid 1-1000 mcg, choline 1-1000 mcg, cobalamin (B12) 1-1000 mcg, vitamin K 1-1000 mcg, boron 1-1000 mcg, calcium 1-1000 mcg, chloride 1-1000 mcg, chromium 1-1000 mcg, cobalt 1-1000 mcg, copper 1-1000 mcg, fluoride 1-1000 mcg, germanium 1-1000 mcg, iodine 1-1000 mcg, iron 1-1000 mcg, magnesium 1-1000 mcg, molybdenum 1-1000 mcg, nickel 1-1000 mcg, potassium 1-1000 mcg, phosphorous 1-1000 mcg, selenium 1-1000 mcg, silicon 1-1000 mcg, sodium 1-1000 mcg, tin 1-1000 mcg, titanium 1-1000 mcg, vanadium 1-1000 mcg, and zinc 1-1000 mcg. The compound is given at increasing capsules following a defined schedule. With increasing defined intervals of time the compound increases the number of adult-derived regenerative pluripotent blastomere-like stem cells circulating in the peripheral vasculature.
We utilized this compound, in a titratable fashion, to convert each participant into their own sterile bioreactor, to provide the requisite number of autologous regenerative pluripotent stem cells to affect a change in their cognitive status. We want to proliferate and then mobilize the connective tissue-resident pluripotent stem cells into the peripheral vasculature in an increasing, titratable, dose-response manner. To facilitate this process, we will apply a compound that mobilizes skeletal muscle connective tissue-resident adult pluripotent stem cells into the peripheral vasculature in an increasing dose-response manner. The compound has been shown to do this in horses (
To date, a collaborator has had over 50 people involved in a 36+ month study with the compound. Most of these people have been diagnosed with COPD (chronic obstructive pulmonary disease) or related lung illness, i.e., Interstitial Pulmonary Fibrosis, Emphysema, Bronchitis, etc. However, there are other participants in this trial that have non-COPD diagnoses, i.e., SLE (systemic lupus erythematosus), Epilepsy, Rotator Cuff Injuries, Cerebral Palsy, Musculoskeletal Diseases, Open Fractures, Osteoarthritis, Lyme's Disease, Cardiac Myopathies, Hypotonia, ALS (amyotrophic lateral sclerosis), Blindness, Spinal Cord Injury, Diabetes, and Parkinson's Disease. There have been no adverse effects of the compound reported on any of these subjects. Indeed, I received two letters from the manufacturer indicating that since 1979 and 1997, respectively, there have been no reported deaths from using their product. In the letter, referencing “1979” they state that every batch is run through extensive testing for microcysten, pesticides, heavy metals, mold, and yeast in five independent laboratories on a regular basis (Appendices). However, the compound does contain a small amount of Vitamin-K, less than 20 micrograms per capsule. Therefore, anyone using Coumadin (Warfarin) as a blood thinner should consult with their physician before using this product.
Several other conditions were reported for humans after the ingestion of the compound, i.e., a decrease in epileptic seizures with concurrent decrease in epileptic medications; healing of rotator cuff injuries; accelerated repair of open torsion bone fractures; less painful osteoarthritic joints; and an increase in cardiac output from 25% to 35% and then from 35% to 45% over two successive six month periods, and it has been six years after his myocardial infarction (anecdotal relative & cardiologist report).
Anecdotally regarding Parkinson disease, four Parkinson's participants have shown a cessation of cognitive decline and either a steady state condition or an increase in cognitive function taking the compound alone (caregiver/relative anecdotal observations). However, one of the participants stopped taking the compound after he had reached his cognitive goal. Unfortunately, cessation of the compound caused a slow reversion back to his decreased PD cognitive state (caregiver/relative anecdotal observations). He is starting to re-take the compound to hopefully regain the cognitive abilities he lost while off the compound.
Unfortunately, an alteration in Parkinson's motor function in PD has not been observed to date in the four Parkinson's patients taking the compound alone. In 2011, a Phase-0 study (everyone gets treated with no placebos, to test efficacy of the procedure) was performed on initially ten PD patients. The subjects took the compound for three months. Unfortunately, two participants dropped out of the study. The eight remaining participants went on to receive an inter-nasal infusion of harvested autologous stem cells into their central nervous system, as well as an aliquot of stem cells IV into their body. Motor, cognitive, affect, adjustment and caregiver variables were monitored over four time periods. Two sets of tests were given before the infusion of autologous stem cells and two sets of tests were given after the infusion of autologous stem cells.
Ten patients were initially recruited for the autologous regenerative pluripotent stem cell therapy. The study population involved subjects with PD diagnosed by Queen Square criteria. Subjects were chosen who had a Modified Hoehn and Yahr Staging 1.5 to 4 (Severe Disability), allowing for a “middle” range of the disease process. Each person selected was assessed at baseline (three months before the stem cell infusion procedure), directly before the procedure, one month after the procedure, and at four months post procedure, for a total of four assessment tests. The subjects took the compound for three months before the autologous stem cell infusion procedure and for four months after the autologous stem cell infusion procedure. At each assessment period, motor changes, as well as assess the overall improvement in cognition, affect, function, adjustment, and caregiver burden, were monitored both before and after autologous stem cell infusion. The areas that were targeted for study included the following Parkinson Assessment Criteria: (1) Motor→UPDRS-III; (2) Cognition→Symbol Digits Modality Test (SDMT), Letter Number Frequency (LNS), RBANS List learning, and Trail Making Part A and B; (3) Affect→Positive and Negative Affect Scale (PANAS), Beck Depression Inventory (BDI-II) and State Trait Anxiety (STAI); (4) Function→Functional Assessment Questionnaire (FAQ) and Schwab and England disability scale; and (5) Overall clinical improvement with the CIBIC-Plus (Clinician's Interview—Based Impression of Change Plus Caregiver Input).
Prior to study entrance, each patient underwent; (1) chart review for medication regimen, medical conditions, and laboratory values, (2) a brief physical examination, and (3) diagnostic dementia evaluations completed by the investigators. The study population involved subjects with Parkinson's disease diagnosed by Queen Square criteria. In addition, subjects were given the Mini Mental State Exam (MMSE) at entry to assure that the level of any dementia was not severe. We wanted to avoid severe dementia in the participants. We applied the RBANS Delayed Memory and selected subjects with lower index scores (typically between 70 and 100). All subjects were taking levodopa or dopamine agonists, MAO-B, or combinations. The subjects may have been on other medications, including cholinesterase inhibitors. We excluded any subject who has had DBS (deep brain stimulation) or had made plans for such. There were subjects with medical co-morbidities as well as other complications (e.g., psychiatric history, living situations, and life habits). We will attempt to adjust for these post hoc.
The initial dosage was 500 mg of the compound, per capsule, oral administration with water on an empty stomach. At baseline (0 mo) the standard dosing regimen of the compound was initiated, i.e., one capsule of compound for 30 days, then two capsules of compound for 30 days, and then three capsules of compound for 30 days. The subject remained on three capsules for the remainder of the experiment, up to four months post autologous regenerative pluripotent stem cell infusion. Consumption of the compound lasted for seven months, during which time there was harvesting and infusion of autologous regenerative pluripotent stem cells into the intra-nasal cavity and into the circulation.
Although there are no known adverse effects associated with taking the compound, a dose reduction process was followed at the conclusion of the study. However, patients were made aware of the possibility of experiencing allergic reactions to the compound.
At seven months into the study subjects began tapering off their compound intake. Subjects who were taking three pills a day will taper to 2 pills a day. Patients continued the titrated amount of 2 pills a day for 2 weeks. Patients were then be titrated down to taking only 1 pill a day for another two weeks. At the end of the two weeks of only taking 1 pill a day, patients were officially halted from their compound intake. Any patients who chose to withdraw during the study (2) adhered to this dose reduction process.
To date, we have been able to harvest autologous pluripotent regenerative stem cells via venipuncture and to do this in a safe manner. To affect motor outcomes we used a non-invasive technique, i.e., intra-nasal infusion (Reger et al., 2008; Danielyan et al., 2009), to effectively move activated regenerative pluripotent stem cells from the peripheral vasculature into the central nervous system. In this procedure, autologous regenerative pluripotent stem cells were placed onto the olfactory mucosa and allowed to migrate into the central nervous system along olfactory projections through the cribiform plate in the ethmoid bone, migrate along the olfactory tracts into the area of the subarachnoid space, from which they could travel throughout the subarachnoid cisterns to reach damaged tissues within the brain and spinal cord.
As a note, it is likely there are other positive outcomes. Once the regenerative pluripotent stem cells are circulating throughout the body, we cannot predict which damaged tissues within the body the regenerative pluripotent stem cells will migrate to and repair first. For example, a collaborator has a Parkinson's patient on one capsule of the compound per day. After four weeks, the patient's cognitive symptoms had not deteriorated, as they had in the past weeks prior to treatment. However, during that same four-week period on the compound, the patient's cardiac ejection fraction increased from 25% to 35%. And then the patient's cardiac ejection fraction increased from 35% to 45% after an additional 6 month period while on the compound. Therefore, we will be keeping note of any potential effects of compound-stimulated regenerative pluripotent stem cells on the functions of other organs throughout the body as well as those particular organs associated with Parkinson's disease.
We are in the preliminary phases with our Phase-0 Parkinson's trial. Our first contingent of Parkinson's patients (8) has been in a phase-0 trial, i.e., everyone gets treated. The patients were all moderate to low (a range of 1.5 to 4.0) with respect to their disease, on a scale of 1-10, with 10 being normal. We are still working on preliminary results (we have not broken the coding system yet), but 4 out of 8 participants are scoring about 9.0 on the scale and 4 out of 8 participants are in the range of 6 to 8 on the scale and are stable. We have one more set of tests to perform before the study is completed and we can then break the coding system. From one of the patient's physicians: “Exciting news. I've had to decrease 1 subject's medications (he insists on coming to see me in Atlanta) and he is doing very well”.
Death and disability from cardiac dysfunction cost the United States nearly 750,000 lives per year. The annual cost of ischemic heart disease is approximately $100 billion [Schoen, 1999]. In most cases of myocardial infarction, an area of the heart muscle become ischemic and proceeds toward dysfunctional scar tissue, Technology leading to repair of damaged myocardium in situ would enable the medical community to change the current treatment modality of medical management to one of regeneration [Chiu, 2001]. Tremendous advances in stem cell technology indicate that it might be possible to effect repair of damaged myocardium via injection of autologous cells. Numerous cell sources have been tried in the effort to repair injured myocardium, including skeletal myoblasts [Mareli et al., 1992; Taylor et al., 1997], fetal and neonatal cardiomyocytes [Koh et al., 1993; Soonpaa et al., 1994], and embryonic stem cells [Klung et al., 1996]. The current peer strategy is to inject live naïve stem cells into and around the area of infarction. It is anticipated that the microenvironment of the heating myocardium direct the naive stem cells to integrate with the existing tissue and to differentiate to form the appropriate cellular phenotypes. Studies have shown that injection of cardiomyocytes leads to improvements in systolic performance, compliance, peri-infarct perfusion, and global ventricular function [Taylor et al., 1998; Sakai et al., 1999; Li et al., 2000]. Injected cardiomyocytes have been shown to form gap junctions with the existing tissue [Reincke et al., 1999]. These results indicate that this is a promising area for further investigation.
The focus of this study was to investigate the possibility of giving the compound alone, without stem cell infusion, to steadily increase the quantity of adult autologous regenerative pluripotent stem cells circulating through the cardiovascular system with increasing dosages of the compound. We would then determine if access to the adult regenerative pluripotent stem cells 24 hours per day for 7 days per week for 4-5 weeks per month for 12 months would affect a healing response, by measuring cardiac output in individuals having a previous myocardial infarction.
The results from a single individual were inadvertently chosen for this study. These results were derived from the aforementioned Parkinson's patient who had had a myocardial infarction six years prior to the initiation of the compound-only Parkinson study. For the previous six years, being tested every six months, this individual demonstrated a cardiac output of 25%. After cessation of Parkinson cognitive decline and stabilization of his Parkinson's symptoms, his heart showed an increase in cardiac output from 25% to 35% after a four month period. After a subsequent six month period on the compound, he demonstrated an increase in cardiac output from 35% to 45%, just taking the compound alone.
Chronic obstructive pulmonary disease (COPD) is the occurrence of both emphysema (damage to the alveolar sacs) and chronic bronchitis (thickening of the cells lining the airways) in an individual [Wikapedia, January, 2012]. Chronic obstructive pulmonary disease results in the pulmonary airways becoming narrowed [NIH, 2010]. This leads to a decrease in the airflow to and from the lungs, causing shortness of breath (dyspnea). In clinical practice, chronic obstructive pulmonary disease is defined by its characteristically low air flow on lung function tests, i.e., FEV-1% [Nathel et al., 2007]. In contrast to asthma, which is reversible, chronic obstructive pulmonary disease is largely irreversible and usually gets progressively worse over time. In the United States, chronic obstructive pulmonary disease is the third leading cause of death. The economic burden in the United States in 2007 was $42.6 billion dollars in lost productivity and health care costs [NHLBI, 2007]. Acquisition of chronic obstructive pulmonary disease can be considered multi-factorial in that smoking, occupational exposures, air pollution, genetics, autoimmune diseases, repeated lung diseases, and a diet high in cured meats (exposure to sodium nitrates) are all contributing factors to development of the disease [MedicineNet.com, 2012; Young et al., 2009; Rennard and Vestbo, 2006; Devereux, 2006; Halbert et al., 2006; Kennedy et al., 2007; MedlinePlus Encyclopedia 000091; Rutgers et al., 2000; Feghali-Bostwick et al., 2008; Lee et al., 2007].
The diagnosis of COPD is confirmed by spirometry [Rabe et al., 2007], a test that measures the forced expiratory volume in one second (FEV1), which is the greatest volume of air that can be breathed out in the first second of a large breath. Spirometry also measures the forced vital capacity (FVC), which is the greatest volume of air that can be breathed out in a whole large breath. Normally, at least 70% of the FVC comes out in the first second (i.e. the FEV1/FVC ratio is >70%). A ratio less than normal defines the patient as having COPD. More specifically, the diagnosis of COPD is made when the FEV1/FVC ratio is <70% [Nathel et al., 2007]. The GOLD criteria also require that values are after bronchodilator medication has been given to make the diagnosis, and the NICE criteria also require FEV1% [Nathel et al., 2007]. According to the ERS criteria, it is FEV1% predicted that defines when a patient has COPD, that is, when FEV1% predicted is <88% for men, or <89% for women [Nathel et al., 2007].
Spirometry can help to determine the severity of COPD [Rabe et al., 2007]. The FEV1 (measured after bronchodilator medication) is expressed as a percentage of a predicted “normal” value based on a person's age, gender, height and weight.
The severity of COPD also depends on the severity of dyspnea and exercise limitation. These and other factors can be combined with spirometry results to obtain a COPD severity score that takes multiple dimensions of the disease into account [Cell et al., 2004].
There is NO known cure for COPD.
COPD usually gradually gets worse over time and can lead to death. The rate at which it gets worse varies between individuals. The factors that predict a poorer prognosis are the following [Rabe et al., 2007].
Five patients were initially recruited for the autologous regenerative pluripotent stem cell therapy. The study population involved subjects with chronic obstructive pulmonary disease. We have chosen subjects that had a FEV1% of less than 30% (Very Severe). Each person selected was assessed at baseline (before the study started) and at termination of the study. The subjects took the compound for three to twelve months before the autologous stem cell infusion procedure, i.e., nebulization with accompanying IV infusion. At the assessment period, we evaluated the change in percentage of FEV 1.
Prior to study entrance, each patient underwent; (1) a chart review for medication regimen, medical conditions, and laboratory values, and (2) a brief physical examination. The study population involved subjects with COPD diagnosed by multiple criteria, including FEV1% of less than 30%.
The initial dosage was 500 mg of the compound, per capsule, oral administration with water on an empty stomach. At baseline (0 mo) the standard dosing regimen of the compound was initiated, i.e., one capsule of compound for 30 days, then two capsules of compound for 30 days, then three capsules of compound for 30 days, then four capsules of compound for 30 days, then five capsules of compound for 30 days, then six capsules of compound for 30 days, then seven capsules of compound for 30 days, then eight capsules of compound for 30 days, then remain on eight capsules of compound for the remainder of the study. Consumption of the compound lasted for 12 months, during which time there was harvesting and infusion of regenerative pluripotent stem cells by nebulization into the lungs and IV infusion into the circulation. Although in the Parkinson study, a dose reduction process occurred, all participants of the COPD study elected to remain on compound until further stem cell treatments could be performed. Patients were made aware of the possibility of experiencing allergic reactions to the compound.
We have the results from two participants thus far, as shown below.
Treatment for HF298 was completed Jul. 20, 2011, after approximately nine months on the compound, while her testing for FEV1 percentage and FVC were not performed until Dec. 9, 2011. As shown, the percentage of forced expiratory volume in 1 second, or FEV1%, for HF298 increased by 60% from her initial FEV1% of 15%. HF298's forced vital capacity, FVC, increased from her initial value of 30% prior to stem cell infusion to a value of 47%. This is an increase of 56.6% from her original value. Since there is no known cure for COPD and the individuals with this disease only spiral downwards towards zero and death, this result is a significant improvement in COPD therapy.
While our second participant showed a percentage difference of 7% for FEV1 and a 5% difference for FVC, these are still significant values, since the expected outcome is a downward spiral leading to death.
Putative stem cells cultured in general induction medium demonstrate CEA-CAM-1 (−) staining, but SSEA-4(+) staining prior to staining for phenotypic expression markers indicative of 63 cell types from all three germ layer lineages: ectoderm, mesoderm, endoderm, but no spermatogonium (suggests cells are pluripotent stem cells=ELSCs).
A: Feline plasma fraction stained with 0.4% Trypan blue. BLSCs are small dark round circles and BLSC-Tr are small glowing structures or structures that have a dark periphery and a clear center, 100× mag. B: Feline plasma fraction stained with CEA-CAM-1. BLSCs are small dark-red round circles and BLSC-Tr are structures with a dark-red periphery and a clear center, 100× mag. C: Canine plasma fraction stained with 0.4% Trypan blue. BLSCs are small dark round circles and BLSC-Tr are structures with a dark periphery and a clear center, 100× mag. D: Canine plasma fraction stained with CEA-CAM-1. BLSCs are small dark-red round circles and BLSC-Tr are structures with a dark-red periphery and a clear center, 100× mag.
A: Ovine plasma fraction stained with 0.4% Trypan blue. BLSCs are small dark round circles, BLSC-Tr are either small glowing structures or structures with a dark periphery and a clear center, 100× mag. B: Ovine plasma fraction stained with CEA-CAM-1. BLSCs are small dark-red round circles, BLSC-Tr are structures with a dark-red periphery and a clear center, and ELSCs are unstained, 100× mag. C: Caprine plasma fraction stained with 0.4% Trypan blue. BLSCs are small dark round circles, BLSC-Tr are either small glowing structures or structures with a dark periphery and a clear center, 100× mag. D: Caprine plasma fraction stained with CEA-CAM-1. BLSCs are small dark-red round circles and BLSC-Tr are structures with a dark-red periphery and a clear center, 100× Mag.
The inventor has unexpectedly discovered that adult-derived regenerative pluripotent transitional blastomere-like stem cells can be obtained from the blood of mammals, particularly from human, (but also mouse, rat, rabbit, cat, dog, sheep, goat, pig, cow, and horse) (
The term “post-natal” as used herein refers to a stage in development of an organism after birth (which may also include premature birth (i.e., at least 60% of normal gestation)). Most typically post-natal stem cells according to the inventive subject matter are isolated from an adult, but earlier stages (e.g., newborn, infant stages, adolescent, prepubescent, or post puberty) are also deemed suitable. Furthermore, the term “totipotent” as used herein in conjunction with a cell refers to a stem cell that has the ability to give rise to placental and/or germ line cells. In addition, the term “pluripotent” as used herein in conjunction with a cell refers to a stem cell that has the ability to give rise, inclusively, to all somatic cells of the embryo/adult, but NOT the embryonic portion of the placenta or the germ line cells, i.e., germ cells (spermatogonia or ova or any of their differentiated cell types).
Remarkably, the adult-derived regenerative pluripotent transitional blastomere-like stem cells derived from post-natal, rather than embryonic tissues are not committed to any tissue lineage and are of a presumed normal karyotype, since both blastomeric-like stem cells and epiblast-like stem cells are of a normal karyotype. Contemplated cells typically express telomerase, Oct-3/4, Sonic hedge-hog, CEA-CAM-1, and/or the CD66e cell surface markers (i.e., HCEA, CEA) and express stage-specific embryonic antigens SSEA (i.e., SSEA-1, SSEA-3, and/or SSEA-4), and the cell surface marker for neutral endopeptidase, CD10. In contrast, adult-derived regenerative pluripotent transitional blastomere-like stem cells typically fail to express BMI-1, IDE1, IDE3, ABCG2, CXCR-4, BCL-2, Nanog, Nanos, CD1a, CD2, CD3, CD4, CD5, CD7, CDB, CD9, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD22, CD23, CD24, CD25, CD31, CD33, CD34, CD36, CD38, CD41, CD42b, CD45, CD49d, CD55, CD56, CD57, CD59, CD61, CD62E, CD65, CD68, CD69, CD71, CD79, CD83, CD90, CD95, CD105, CD106, CD117, CD123, CD135, CD166, Glycophorin-A, MHC-I, HLA-DRII, FMC-7, Annexin-V, and/or LIN cell surface markers.
It should be especially appreciated that the adult-derived regenerative pluripotent transitional blastomere-like stem cells according to the inventive subject matter remain quiescent in serum-free defined medium in the absence of differentiation inhibitory agents (e.g., leukemia inhibitory factor, or anti-differentiation factor), and when implanted into animals do not form cancerous tissues. In concordance, implanted adult-derived regenerative pluripotent transitional blastomere-like stem cells remain quiescent after implantation or incorporate into all tissues undergoing repair.
It should be further noted that the adult-derived regenerative pluripotent transitional blastomere-like stem cells presented herein can also be stimulated in vivo as well as in vitro to proliferate (most typically in response to one or more growth factors (in vitro) or in response to the compound (in vivo)). Remarkably, when stimulated, post-natal adult-derived regenerative pluripotent transitional blastomere-like stem cells exhibit extended self-renewal as long as they remain lineage-uncommitted. Furthermore, the adult-derived regenerative pluripotent transitional blastomere-like stem cells are not contact inhibited at confluence, they require a substratum for growth in vitro and demonstrate telomerase activity.
The inventor further discovered that adult-derived regenerative pluripotent transitional blastomere-like stem cells have the ability to generate all tissues of the conceptus, and all somatic cells of the embryo/fetus from all three germ layer lineages, EXCEPT embryonic/fetal portions of the placenta, and germ cells, In this regard; they mimic pluripotent epiblast-like stem cells.
After extended exposure to a range of dexamethasone concentrations, adult-derived regenerative pluripotent transitional blastomere-like stem cells differentiated into more than 50 discrete cell types. The induced cell types exhibited characteristic morphological and phenotypic expression markers for pluripotent epiblastic-like stem cells, ectodermal germ layer lineage stem cells, epidermal progenitor cells, epidermal cells, neuronal progenitor cells, dopaminergic neurons, pyramidal neurons, other types of neurons, astrocytes, oligodendrocytes, radial glial cells, ganglion cells, endodermal germ layer lineage stem cells, gastrointestinal epithelial cells, hepatic progenitor cells, hepatocytes, bile canalicular cells, oval cells, pancreatic progenitor cells, pancreatic ductal cells, pancreatic alpha-cells, pancreatic beta-cells, pancreatic delta-cells, three-dimensional pancreatic islets, mesodermal germ layer lineage stem cells, muscle progenitor cells, skeletal muscle, smooth muscle, cardiac muscle, adipogenic progenitor cells, white fat, brown fat, chondrogenic progenitor cells, hyaline cartilage, articular cartilage, growth plate cartilage, elastic cartilage, fibrocartilage, fibrogenic progenitor cells, tendon, ligament, scar tissue, dermis, osteogenic progenitor cells, cancellous bone, trabecular bone, woven bone, lamellar bone, osteoblasts, osteocytes, osteoclasts, endotheliogenic progenitor cells, endothelial cells, hematopoietic progenitor cells, erythrocytes, macrophages, B-cell lymphocytes, and T-cell lymphocytes.
Such induced unidirectional lineage-commitment process necessitates the use of either general induction agents or inductive agents that cause the cell to differentiate into specific tissue lineages. It is contemplated that once adult-derived regenerative pluripotent transitional blastomere-like stem cells are induced to commit to pluripotent epiblast-like stem cells, they have four options. The stem cells can (a) apoptose, (b) remain quiescent, (c) proliferate, or (d) differentiate into ectodermal, endodermal, and/or mesodermal germ layer lineage stem cells. Similarly, once pluripotent epiblastic-like stem cells are induced to commit to form ectodermal, endodermal, and/or mesodermal germ layer lineage stem cells, they have four options as well. The stem cells can (a) apoptose, (b) remain quiescent, (c) proliferate, or (d) differentiate into lineage-committed progenitor cells characteristic of specific tissue lineages. Once committed to specific tissue lineages, they assume the characteristics of lineage-specific progenitor cells, which again can (a) apoptose, (b) remain quiescent, (c) proliferate, or (d) uni-directionally progress down their differentiation pathway, under the influence of specific agents. As committed progenitor cells, their ability to replicate is limited to approximately 50-70 cell doublings (human) or 8-10 cell doublings (rodent) before programmed cell senescence and cell death occurs.
Consequently, it should be recognized that human adult-derived regenerative pluripotent transitional blastomere-like stem cells can be obtained in a relatively simple manner by extraction from autologous circulating blood after stimulation by the compound, and thereafter expanded without ever having to leave the individual. Indeed, previous experiments by the inventor have shown that the cells according to the inventive subject matter can undergo at least 100 population doublings in situ and maintain their undifferentiated state. Therefore, it should be recognized that these cells do not spontaneously differentiate in situ, but remain in an undifferentiated state. Once sufficient quantities of adult-derived regenerative pluripotent transitional blastomere-like stem cells are obtained (with or without expansion), they may be implanted into a human without teratoma formation, and will remain quiescent unless in the presence of damaged, necrotic, and/or inflamed tissue undergoing repair. Alternatively, contemplated adult-derived regenerative pluripotent transitional blastomere-like stem cells may be expanded in vivo and then subjected to differentiation steps to thereby generate pluripotent stem cells (e.g., epiblast-like stem cells), germ layer lineage stem cells (e.g., those forming ectodermal cells, mesodermal cells, and endodermal cells), and/or progenitor cells (e.g., multipotent cells, tripotent cells, bipotent cells, and unipotent cells) in quantities that would otherwise be difficult, if not even impossible to obtain. Moreover, it should be recognized that such cells will be available for implantation into a donor with either an autologous or allogeneic match.
1DC, differentiated cells
2PC, progenitor cells
3GLSC, germ layer lineage stem cell
4ELSC, epiblast-like stem cell
5Tr-BLSC, adult-derived regenerative pluripotent transitional blastomere-like stem cell
6BLSC, blastomeric-like stem cell
7Var, variable
8Viabil P. Mortem, viability of tissue post mortem (after removal from the body) stored at 4° C.
9STs, solid tissues
10CTs, connective tissues
11BM, bone marrow
12Bld, blood
13Qui, quiescence
14NA, not applicable
15Tel'ase, telomerase
16PD, population doublings
17PR, proliferation rate
18D-W, days to weeks
19CD, cell doublings
20NYD, not yet determined
21CI-C, cell inhibition at confluence
22GT-1C, growth on type-1 collagen substrate
23G-S, growth in cell suspension cultures
24R-Prolif, response to proliferation factors
25R-Prog, response to progression agents
26R-Induc, response to induction factors
27R-Inhib, response to inhibitory factors
28#Cs-Fr, number of cells frozen per aliquot
29Freeze Agent, cryopreservation agent
30DMSO, dimethyl sulfoxide, 99.99% pure
31Temp, optimum freezing temperature in centigrade
32FrProc, freezing process
33ThwProc, thawing process
34Recov, % recovery from freezing process
35RC-1C, rat clones derived from one cell
36CsFmd, cells formed
37CD-Ms, cluster of differentiation (CD) markers
This application is a continuation-in-part of U.S. patent application Ser. No. 13/363,370 entitled “ADULT-DERIVED REGENERATIVE PLURIPOTENT TRANSITIONAL BLASTOMERE-LIKE STEM CELLS AND METHODS FOR IDENTIFICATION, PROLIFERATION, HARVESTING, SEPARATION, AND TRANSPLANTATION THEREOF,” filed 31 Jan. 2012. U.S. patent application Ser. No. 13/363,370 claims the benefit of and priority to U.S. Prov. Pat. App. Ser. No. 61/437,705, filed Jan. 31, 2011. Each of the above listed applications are incorporated herein by referent in their entireties.
Number | Date | Country | |
---|---|---|---|
61437705 | Jan 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13363370 | Jan 2012 | US |
Child | 13365880 | US |